Sanofi SA expanded its portfolio of new technologies with the acquisition on 9 April of the US preclinical stage biotech company Tidal Therapeutics which has developed an approach for reprogramming immune cells in vivo using messenger RNA (mRNA). “We anticipate that this next generation, off-the-shelf approach, has the potential to bring CAR T cell therapy to a much broader patient population,” said Frank Nestle, Sanofi’s chief scientific officer, in a prepared statement.
